A new study published in the journal Nature found that a personalized vaccine, named autogene cevumeran, is showing promising results for treating pancreatic cancer, one of the deadliest malignancies.
Chinese researchers have developed a “cocktail” nanovaccine to prevent plaque from building up in the arteries, an underlying factor in heart disease, which is the leading cause of death worldwide.
Scientists at the University of Cambridge, who have been investigating how certain common medications might hold back the movement of cancer cells, have found that daily low-dose aspirin use could curb the spread of certain cancers, including breast and prostate tumors.
A recent study found there is significantly higher intravenous immune globulin (IVIG) resistance among children who contracted COVID-19 before developing Kawasaki disease (KD).
The U.S. Food and Drug Administration has awarded fast track designation to Adicet Bio’s novel allogeneic gamma delta CAR-T-cell therapy ADI-001 for adults with refractory systemic lupus erythematosus with extrarenal involvement.
A study published in Frontiers in Immunology has found the administration of intravenous immune globulin (IVIG) is associated with a reduction in sepsis mortality and favorable outcomes in laboratory parameters and the functional status, contributing to the ongoing debate on the efficacy of IVIG for sepsis.
The U.S. Food and Drug Administration (FDA) has expanded its approval of Dupixent to chronic obstructive pulmonary disease (COPD).
A study conducted by researchers at Weill Cornell Medicine has demonstrated that a series of six vaccinations containing a modified protein from the surface of HIV particles stimulated initial steps of a potent immune response in young nonhuman primates.
Researchers at the Terasaki Institute for Biomedical Innovation have been awarded a multi-million dollar grant from the NIH to advance research in organ transplantation and antibody mediated rejection.
The U.S. Department of Health and Human Services, through the Centers for Medicare and Medicaid Services, has released final guidance outlining the process for the second cycle of negotiations under the Medicare Drug Price Negotiation Program.